Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: 111In, 131I, 99mTc, and 188Re

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Van Schaijk, Frank G ^a   Oosterwijk, Egbert ^a   Soede, Annemiele C ^a   Oyen, Wim J G ^a   McBride, William J ^b   Griffiths, Gary L ^b   Goldenberg, David M ^b   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLLYSYL(PENTETIC ACID) TYROSYLLYSYL(PENTETIC ACID) LYSYL(THIOSEMICARBONYLGLYOXYLCYSTEINYL)AMIDE; ACETYLPHENYLLYSYL(PENTETIC ACID) TYROSYLLYSYL(PENTETIC ACID)AMIDE; BISPECIFIC ANTIBODY; DIPENTETATE INDIUM IN 111; DIPENTETATE IODINE I 131; DIPENTETATE RHENIUM RE 188; DIPENTETATE TECHNETIUM TC 99M; IMP 156; IMP 192; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY G250 PENTETIC ACID IN 111; PENTETIC ACID; PEPTIDE FRAGMENT; RHENIUM 188; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; ISOTOPE LABELING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRETARGETED RADIOIMMUNOTHERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SOLID TUMOR;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; LYSINE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PENTETIC ACID; PEPTIDES; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; TECHNETIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0141791449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Goldenberg, D. M., DeLand, F., Kim, E., Bennett, S., Primus, F. J., van Nagell, J. R., Estes, N., DeSimone, P., and Rayburn, P. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N. Engl. J. Med., 298: 1384-1386, 1978.
2. Goldenberg, D. M. An introduction to the radioimmunodetection of cancer. Cancer Res., 40: 2957-2959, 1980.
3. Goldenberg, D. M., Gaffar, S. A., Bennett, S. J., and Beach, J. L. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res., 41: 4354-4360, 1981.
4. Knox, S. J., and Meredith, R. F. Clinical radioimmunotherapy. Semin. Radiat. Oncol., 10: 73-93, 2000.
5. Jurcic, J. G., and Scheinberg, D. A. Radioimmunotherapy of hematological cancer: problems and progress. Clin. Cancer Res., 1: 1439-1446, 1995.
6. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res., 47: 5672-5677, 1987.
7. Goodwin, D. A., Mears, C. F., McTigue, M., and David, G. S. Monoclonal antibody hapten radiopharmaceutical delivery. Nucl. Med. Commun., 7: 569-580, 1986.
8. Boerman, O. C., Kranenborg, M. H., Oosterwijk, E., Griffiths, G. L., McBride, W. J., Oyen, W. J., de Weijert, M., Oosterwijk-Wakka, J., Hansen, H. J., and Corstens, F. H. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res., 59: 4400-4405, 1999.
9. 188Re-labeled peptide. Bioconjug. Chem., 11: 842-854, 2000.
10. Gruaz-Guyon, A., Janevik-Ivanovska, E., Raguin, O., Labriolle-Vaylet, C., and Barbet, J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q. J. Nucl. Med., 45: 201-206, 2001.
11. 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J. Nucl. Med., 42: 146-153, 2001.
12. Boerman, O. C., Van Schaijk, F. G., Oyen, W. J. G., and Corstens, F. H. M. Pretargeted radioimmunotherapy of cancer: progress step-by-step. J. Nucl. Med., 44: 400-411, 2003.
13. Barbet, J., Kraeber-Bodere, F., Vuillez, J. P., Gautherot, E., Rouvier, E., and Chatal, J. F. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm., 14: 153-166, 1999.
14. Kranenborg, M. H., Boerman, O. C., Oosterwijk-Wakka, J. C., de Weijert, M. C., Corstens, F. H., and Oosterwijk, E. Development and characterization of anti-renal cell carcinoma X antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res., 55: 5864s-5867s, 1995.
15. Pastorek, J., Pastorekova, S., Callebaut, I., Mornon, J. P., Zelnik, V., Opavsky, R., Zat'ovicova, M., Liao, S., Portetelle, D., Stanbridge, E. J., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 9: 2877-2888, 1994.
16. Uemura, H., Nakagawa, Y., Yoshida, K., Saga, S., Yoshikawa, K., Hirao, Y., and Oosterwijk, E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer, 81: 741-746, 1999.
17. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., and Warnaar, S. O. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer, 38: 489-494, 1986.
18. 188Re generator. J. Nucl. Med., 41: 1271-1278, 2000.
19. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegel, J. A., and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
20. Griffiths, G. L., Goldenberg, D. M., Knapp, F. F., Jr., Callahan, A. P., Chang, C. H., and Hansen, H. J. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res., 51: 4594-4602, 1991.
21. Shih, L. B., Thorpe, S. R., Griffiths, G. L., Diril, H., Ong, G. L., Hansen, H. J., Goldenberg, D. M., and Mattes, M. J. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J. Nucl. Med., 35: 899-908, 1994.